The Mirage of Miracle Cures: Hydroxychloroquine and Ivermectin in COVID-19

Abstract

The global coronavirus disease 2019 (COVID-19) pandemic created unprecedented urgency for effective therapeutic interventions. In the absence of specific antivirals or vaccines during the early phase, hydroxychloroquine (HCQ) and ivermectin (IVM) emerged as widely promoted candidates based on in vitro antiviral activity, theoretical mechanisms, and anecdotal reports. Both drugs rapidly entered clinical practice and national policies despite major pharmacological and methodological limitations. Large randomized controlled trials, including RECOVERY, Solidarity, TOGETHER, ACTIV-6, and PRINCIPLE, consistently demonstrated no meaningful benefit of HCQ or IVM in the prevention or treatment of COVID-19, while HCQ was associated with increased cardiac risk. Regulatory authorities such as the FDA, EMA, and WHO subsequently restricted their use to formal clinical trial settings. However, politicization, media amplification, and the publication of low-quality or fraudulent studies contributed to misinformation, inappropriate prescribing, and patient harm. These events exposed systemic weaknesses in global pandemic responses, including premature reliance on poor-quality evidence, limited transparency in communication, and the influence of political and commercial interests. The rise and fall of HCQ and IVM highlight the importance of conducting rapid yet rigorous clinical trials, upholding evidence-based standards, and implementing proactive measures against misinformation to preserve scientific integrity and public trust during future health emergencies.